ep exce consensu pahc ep
beat estim better revenu profit howev initi
ep guidanc fall short estim
consensu necessari
product
develop initi consequ reduc ep
reflect step oper expens near term
revenu profit prevail revenu rose ahead plan
stronger anim health handili view mfa
acceler
nutrit spec vs disappoint dairi headwind
vaccin vs also plan despit intern
strength loss us distribut contract gross margin dip
bp bp plan sg fell bp bp plan drive
ebitda margin expans bp bp ahead estim
gener million cash cash reserv stand million
share may ebb share ytd vs
momentum may subsid initi ep guidanc fall
short consensu take necessari step diversifi portfolio
benefit nt invest materi month
said encourag strong core ah sale ttm
revenu us repres total impli greater stabil
across highli regul categori note bump dividend
also bright spot call commentari focu demand trend implic
global trade/nafta dynam new develop efforts/associ
cost share current trade ep premium
diversifi industri leader contribut neutral view
risk shift regulatori demand environ
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
lead manufactur anim health product
concentr product anim product prevent control
treat diseas enhanc health nutrit overal
product livestock
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
challeng relat antibiot use greater expect ramp
faster-grow subsector anim health vaccin nutrit
specialti favor epidemiolog weather
macroeconom trend influenc underli util trend
consider pick us intern livestock
grey sky valuat assum harsher expect
regulatori challeng global use antibiot medicin feed
addit weak global livestock demand
 close
latest revenu upsid encourag acceler sale offset
slightli weaker expect trend across faster-grow profit sub-seg
vaccin nutrit specialti repres third consecut quarter
acceler revenu sub-seg experienc declin throughout
vdf-relat headwind notabl sale vaccin increas
lacklust dairi fundament continu weigh nutrit specialti contribut
rel flat growth quarter well plan
initi top-line guidanc exceed view call slower growth across
core anim health unit includ l-msd growth mfa continu
intern strength stabl us trend hsd vaccin impact us distribut
contract loss dd nutrit specialti
importantli initi ep guidanc fall short estim
consensu necessari increment invest product develop
initi remind announc enter agreement develop
canin lyme diseas vaccin notabl entranc faster-grow companion
anim speci segment consequ incur increment cost associ
effort along potenti develop effort partnership focus
nutrit vaccin segment across product companion anim speci
group compani target contribut effort materi longer
term next month make hard-hit catalyst longer term
natur ebitda expect declin bp yoy bp
improv gross margin mix off-set aforement increment
invest capit expenditur also expand million
million dedic state increas capac manufactur initi
figur quarterli revenu growth segment
anim health revenu
s/other revenu segment revenu increas well ahead
flat estim addit penetr cattl sector intern strength
benefit unquantifi acquisit
nutrit specialti revenu growth nutrit specialti
well plan continu pressur across dairi segment
vaccin revenu vaccin sale increas vs estimate despit
volum growth outsid us within us reduc diseas pressur like
soften growth well competit dynam view
miner nutrit revenu
miner nutrit revenu view vs estimate driven higher
price associ rise underli raw materi cost miner nutrit least
profit busi expect meaning growth driver
extend histori busi industry-lead presenc extens relationship
across suppli chain help unlock cross sell opportun broader
perform product revenu
perform product revenu growth vs estimate higher volum
price copper-bas product divest portion perform
product busi past sever year expect continu
deemphas segment opportunist divestitur go forward profit within
segment remain rel low ebitda margin greater focu
higher margin anim health busi bode well profit profil
quarter gener million cash cash reserv stand
million capit deploy strategi remain focus de-lever dividend
tuck-in acquisit partnership supplement growth
expect revenu growth reflect growth anim health
miner nutrit perform product ebitda margin
lower aforement increment invest higher revenu along
rel flat interest tax expens pursuant tax reform drive ep growth
expect ep grow revenu growth
assum rel stabl fundament across us livestock industri build
momentum cross-market intern strategi forecast ebitda
margin expans bp better product mix oper effici
ep ev/ebitda current trade premium
histor averag respect despit slower growth profil
contribut neutral view price target base multipl
compani mention price
